NCT05312801 - Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

May 1, 2025

Study Completion Date

September 2, 2025

Conditions

Lymphoma, Non-Hodgkin Lymphoma, B-Cell

Interventions

DRUG

BAFF CAR-T

Autologous CAR-T cell therapy expressing the BAFF-ligand.

Trial Locations (2)

NOT_YET_RECRUITING

University Hospitals Seidman Cancer Center, Cleveland

RECRUITING

"Taussig Cancer Institute , Cleveland Clinic"